Tanya Borsuk

Tanya Borsuk has a diverse work experience in the biotech and pharmaceutical industry. Tanya is currently serving as an Independent Board Member at TIAP - Toronto Innovation Acceleration Partners and Redesign Science since 2023 and 2022 respectively. Prior to this, they held the role of Executive VP of Corporate and Business Development at Congruence Therapeutics in 2022. From 2021 to 2022, they worked as the Chief Business Officer at Sitryx. Before that, they held roles at Flagship Pioneering, Bristol Myers Squibb, Celgene, Eisai Inc., Rutgers University- Masters of Business and Science Program, and Nuvera Life Science Consulting, where they held various positions in business development, strategy, market analytics, and advisory board membership.

Tanya Borsuk's education history starts with their enrollment at Woodland Public School and Thornhill Secondary School, although the specific years are not provided. Tanya then pursued a Bachelor of Science degree in Biology/Microbiology from Queen's University from 1997 to 2001. Following this, they attended Rutgers University from 2001 to 2007, where they obtained a PhD in Cell/Cellular and Molecular Biology. In 2007, they also completed a Mini-MBA in Business Administration at Rutgers University.